Clinical trial · no report yet · Phase 3
LOTIS 5
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT04384484 ↗
- Active not recruiting
- ADC Therapeutics S.A.
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| YouTube | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Loncastuximab Tesirine; Rituximab; Gemcitabine; Oxaliplatin
- Arms
- Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R) · Experimental
- Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R) · Experimental
- Part 2: Standard Immunochemotherapy (R-GemOx) · Active comparator
- Enrollment
- 440
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- ADC Therapeutics S.A.
- Start
- Sep 16, 2020
- Primary completion
- Mar 31, 2026
- Results posted
- No
- Registry record
- NCT04384484 · updated Apr 28, 2026